ME00569B - Poboljšana bakterijska vakcina mycoplasma hyopneumoniae - Google Patents

Poboljšana bakterijska vakcina mycoplasma hyopneumoniae

Info

Publication number
ME00569B
ME00569B MEP-2008-858A MEP85808A ME00569B ME 00569 B ME00569 B ME 00569B ME P85808 A MEP85808 A ME P85808A ME 00569 B ME00569 B ME 00569B
Authority
ME
Montenegro
Prior art keywords
vaccine composition
mixture
mycoplasma hyopneumoniae
group
siv
Prior art date
Application number
MEP-2008-858A
Other languages
English (en)
Inventor
Hsien-Jue Chu
Wumin Li
Zhichang Xu
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32680190&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME00569(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of ME00569B publication Critical patent/ME00569B/me
Publication of ME00569A publication Critical patent/ME00569A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Pronalazak obezbeđuje poboljšanu kompoziciju bakterijske vakcine Mycoplasma hyopneumoniae, koja poželjno obezbeđuje imunitet od infekcija posle jednog davanja. Kompozicija se sastoji od inaktivirane bakterije Mycoplasma hyopneumoniae i smeše pomoćnih sredstava, koje u kombinaciji, obezbeđuju imunitet naspram Mycoplasma hyopneumoniae infekcije posle jednog davanja i izazivaju imuni odgovor specifičan na bakteriju Mycoplasma hyopneumoniae, uključujući imunitet posredovan ćelijama i lokalni (sekrecija IgA) imunitet. U poželjnom izvođenju, smeša pomoćnih sredstava se sastoji od polimera akrilne kiseline, najpoželjnije Carbopol-a i smeše metaboličnog ulja, kao što su jednom ili više nezasićeni terpenski ugljovodonici poželjno skvalen ili skvalan i polioksietilenpolioksipropilen blok kopolimera kao što je Pluronic®. Kompozicija vakcine može opciono uključivati konzervanse, poželjno timerosol i/iliEDTA. U još jednom izvođenju, pronalazak obezbeđuje poboljšanu kompoziciju vakcine naspram Mycopfasma hyopneumoniae, koja poželjno obezbeđuje imunitet od infekcije posle jednog davanja i sastoji se od inaktivirane Mycoplasma hyopneumoniae bakterije i pomoćnog sredstva ili smeše pomoćnih sredstava koje u kombinaciji obezbeđuju imunitet naspram Mycoplasma hyopneumoniae infekcije posle jednog davanja i izazivaju specifični imuni odgovor na Mycoplasma hyopneumoniae bakteriju uključuju imunitet posredovan ćelijama i lokalni (sekrecija IgA) imunitet u kombinaciji sa ostalim komponentama vakcine.

Claims (22)

1. Kompozicija vakcine za imunizaciju životinja protiv infekcije Mycoplasma hyopneumoniae i viralnog patogena, naznačena time, što uključujeimunizirajuću količinu bakterije Mycoplasma hyopneumoniae;imunizirajuću količinu bar jednog virusnog antigena i za branog iz grupe koju čine virus svinjskog gripa (SIV), v irus svinjskog r produktivnog i respiratmnog sindroma (PRRSV) svinjski cirkovirus (PCV);smešu pomoćnih sredstava koju čine polimer akr ilne kiseline i smeša metaboličnog ulja i polioksietilen-polioksipropilen blok kopolimera; ifarmaceutski prihvatljiv nosač, gde kompozicija vakcine posle jednog davanja t zazJva zaštitni imunitet od Mycoplasma hyopnewnoniae.
2. Kompozicija vakcine prema zahtevu l, naznačena time, što se smeša pomoćnih sredstava sastoj i od polimera akrilne k i se line i smeše metaboličnog ulja koje se sastoji od jednog ili v i še terpenskih ugljovodonika i polioksieti lena i polioksieti len-p olioksipropilen blok kopolimera u odnosu od oko 1:25 do 1:50 polimera akr iln e kiseline u odnosu na smeš u metabolično ulje/po lioksieti len-pol ioksipropilen blok kopolimera.
3. Kompozicija vakcine prema zahtevu l , naznačena time, što smeša pomoćnih sredstava čini oko 1-25% v/v kompozicije vakcine.
4. Kompozicija vakcine prema zahtevu 3, naznačena time, š to polimer akrilne kiseline je prisutan u koncentracUi od oko l% v/v i smeša terpenski ugljovodonici/polioksietilen-polioksipropi len b lok kopolimer je prisutna u krajnjoj koncentraciji od oko 5% do l 0% v/v.
5. Kompozicija vakcine prema zahtevu 3, naznačena time, što smeša pomoćnih sredstava se sastoji od oko 2%-15% v/v kompozicije vakcine.
6. Kompozicija vakcine prema zahtevu 5, naznačena time, što smeša pomoćnih sredstava se sastoji od oko 5%-12% v/v kompozicije vakcine.
7. Kompozicija vakcine prema zahtevu 1, naznačena time, što metabolično ulje je skvalan ili skvalen.
8. Kompozicija vakcine prema zahtevu 6 ili 7, naznačena time, što polimer akrilne kiseline je karbomer.
9. Kompozicija vakcine prema bilo kom zahtevu 1-8, naznačena time, što dalje uključuje bar jednu bakteriju izabranu iz grupe koju čine Haemonphilus parasuis, Pasteurella multiocida, Streptococcum suis, Actionobacillus pleuropneumoniae, Bordetella bronchiseptica, Salmonella choleraesuis, Erysipelothrix rhusiopathiae i bakterija leptospire.
10. Kompozicija vakcine prema bilo kog od zahteva 1-8, naznačen time, što se dalje sastoji od bakterijskog ili virusnog antigena izabranog od jedne ili više od sledećih grupa, SIV; Haemonphilus parasuis; grupa se sastoji od PRRSV i PCV; grupa se sastoji od SIV i Erysipelothrix rhusiopathiae: grupa se sastoji od Pasteurella multiocida i Bord etella bronchiseptica .
11. Postupak zaštite životinja protiv bolesti uzrokovane sa Mycoplasma hyopneumoniae i bar još jednim virusnih antigenom, naznačen time, što uključuje stupanj davanja pomenutoj životinji kompozicije vakcine koja se sastoji od imunizirejuće kotičine bakterije Mycoplasma hyo.pneumoniae ; imunizirajuće količine bar jednog virusnog antigena izabranog iz grupe koju čine virus svinjskog gripa (SIV), virus svinjskog reproduktivnog i respiratornog sindroma (PRRSV) i svinjski cirkovirus (PCV); smeše pomoćnih sredstava koju čine polimer akrilne kiseline i smeša metaboličnog ulja i polioksietilen-polioksipropilen blok kopolimera; i farmaceutski prihvatljivog nosača, gde kompozicija vakcine posle jednog davanja izaziva zaštitni imunitet od infekcije Mycoplasma hyopneumoniae.
12. Postupak prema zahtevu 11, naznačen time, što imunizirajuća količina pomenute bakterije je oko lxl08 do 3xl0 11 MHDCE/ml.
13. Postupak prema zahtevu 12, naznačen time, što imunizirajuća količina pomenute bakterije je oko lx l 0 9 do 3x l 09 MHDCE/ml.
14. Postupak prema zahtevu 11, naznačen time, što način davanja u pomenutom stupnju davanja je intramuskularni, subkutanozni, intraperitonealni, aerosolom, oralno ili intranazalno.
15. Postupak prema zahtevu 11, naznačen time, što smeša pomoćnih sredstava se sastoji od polimera akrilne kiseline i smeše metaboličnog ulja koje čine jedan ili više terpenskih ugljovodonika i polioksietilen polioksipropilen blok kopolimera prisutan u krajnjoj koncentraciji od oko 1-25% v/v.
16. Postupak prema zahtevu 15, naznačen time, što polii·ner akrilne kiseline smeše pomoćnih sredstava je karbomer.
17. Postupak prema zahtevu 15, naznačen time, što metabolično ulje smeše pomoćnih sredstava je terpenski ugljovodonik izabran iz grupe koju čine skvalen i skvalan.
18. Postupak prema bilo kom od zahteva 11-17, naznačen t im e, što se dalje sastoji od zajedničkog davanja bar jedne dodatne bakteri je izabrane iz grupe koju čine Haemonphilus parasuis, Pasteurella n1.ultiocida, Streptococcum suis, Actionobacitlus pleuropneumoniae, Bordetetla bronchiseptica, Salmone/la choleraesuis, Erysipelothrix rhusiopathiae i bakterija leptospire.
19. Postupak prema zahtevima 11-17 za zaštitu ž i votinja naspram bolesti izazvnih sa Mycoplasma hyopneumoniae i bar jednog virusnog patogena i bar jednog dodatnog patogena, naznačen time, što dalje ukUučuje zajedničko davanje bar jednog dodatnog bakterijskog ili virusnog antigena izabranog od jednog ili više bakteriskih ili virusnih antigena izabranih iz jedne ili više sledećih grupa SIV; Haemonphilus parasuis; gmpe koja se sastoji od PRRSV i PCV; grup·e koja se sastoji od SIV i Erysipelothrix rhusiopathiae; grupe koja se sastoji od Pasteurellamultiocida i Bordetella bronchiseptica.
20. Kompozicija vakcine za imuniziranje životinja naspram infekcije Mycoplasma hyopneumoniae i virusnog patogena, naznačena time, što se sastoji od imunizirajuće količine bakterije Mycoplasma hyopneumoniae ; imunizirajuće količine bar jednog virusnog antigena izabranog iz grupe koju čine Haemonphilus parasuis, Pasteurella multiocida, Streptococcum suis, Actionobacillus pleuropneumoniae, Bordetella bronchiseptica, Salmone /la choleraesuis, Erysipelothrix rhusiopathiae, bakterija leptospira, virus svinjskog gripa (SIV), virus svinjskog reproduktivnog ·i respiratornog sindroma (PRRSV) i svinjski cirkovirus (PCV); bar jedno pomoćno sredstvo; i farmaceutski prihvatljivog nosača, gde kompozicija vakcine posle jednog davanja izaziva zaštitni imunitet od infekcije Mycoplasma hyopnewnoniae.
21. Kompozicija vakcine prem a zahtevu 20, naznačena time, što dalje sadrži bakterijski i virusni antigen i zabran iz jedne ili više sledećih grupa, SIV; Haemonphilus parasuis; grupe koja se sastoji od PRRSV i PCV; grupe koja se sastoj i od SIV i Erysipelothrix rhusiopath.iae; grupe koja se sastoji od Pasteurella multiocida i, Bor det ella bronchiseptica.
22. Kompozicija vakcine za imuniziranje ži vot in ja naspram infekcija f.1ycoplasma hyopneumoniae i v iru snih patogena, naznačena time, š to se sastoji od imunizirajuće količine bakterije f.1ycoplasma h.yopneum on.iae ; imunizirajuće količine bar jednog virusnog antigena i zabran og iz grupe koju čine virus svinjskog gripa (SIV), virus svinjskog reproduktivnog i respiratornog sindroma (PRRSV) svinjski cirkovirus (PCV); smešu pomoćnih sredstava koju čine polimer akri lne kise l ine i metaboličnog ulje i polioksietilen-polioksipropil en blok kopol i mer u obliku emulzije ulja u vodi; i gde kompozicija vakcine posle jednog davanja izaziva zaštitni imunitet od Mycoplasma hyopneumoniae .
MEP-858/08A 2002-05-17 2003-05-14 Improved mycoplasma hyopneumoniae bacterin vaccine ME00569A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/150,597 US7018638B2 (en) 2000-12-19 2002-05-17 Mycoplasma hyopneumoniae bacterin vaccine
PCT/US2003/015115 WO2004058142A2 (en) 2002-05-17 2003-05-14 Improved combine vaccine against mycoplasma hyopneumoniae and porcine viruses

Publications (2)

Publication Number Publication Date
ME00569B true ME00569B (me) 2011-12-20
ME00569A ME00569A (en) 2011-12-20

Family

ID=32680190

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-858/08A ME00569A (en) 2002-05-17 2003-05-14 Improved mycoplasma hyopneumoniae bacterin vaccine

Country Status (19)

Country Link
US (4) US7018638B2 (me)
EP (2) EP1506006B1 (me)
JP (2) JP2006515304A (me)
KR (1) KR101056622B1 (me)
CN (1) CN1305524C (me)
AR (1) AR039545A1 (me)
AU (1) AU2003303129B2 (me)
BR (1) BR0310082A (me)
CL (1) CL2010000397A1 (me)
DK (1) DK1870109T3 (me)
ES (2) ES2569063T3 (me)
HR (1) HRP20041068B1 (me)
ME (1) ME00569A (me)
MX (1) MXPA04011218A (me)
NZ (1) NZ537014A (me)
RS (1) RS54390B1 (me)
TW (1) TWI320715B (me)
WO (1) WO2004058142A2 (me)
ZA (1) ZA200410153B (me)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39494E1 (en) * 1992-02-27 2007-02-27 Intervet Inc. Inactivated mycoplasma hyopneumoniae and uses therefor
US6316005B1 (en) * 1994-04-11 2001-11-13 Solvay Animal Health, Inc. Borrelia burgdorferi bacterin
EP0839912A1 (en) * 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
US20040224327A1 (en) * 1996-10-30 2004-11-11 Meulenberg Johanna Jacoba Maria Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
CA2366072C (en) * 1999-03-08 2007-07-10 Id-Lelystad, Instituut Voor Dierhouderij En Diergezondheid B.V. Prrsv vaccines
ES2348159T3 (es) * 1999-04-22 2010-11-30 United States Department Of Agriculture Vacuna contra el sindrome respiratorio y reproductivo porcino basada en el aislado ja-142.
MY128159A (en) * 2000-06-30 2007-01-31 Wyeth Corp Methods and composition for oral vaccination
MY129765A (en) * 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
US7320793B2 (en) * 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
TWI238721B (en) * 2003-06-20 2005-09-01 Animal Technology Inst Taiwan Swine enzootic vaccine, its producing method and usage
TW200604526A (en) * 2004-06-18 2006-02-01 Unviersity Of Minnesota Identifying virally infected and vaccinated organisms
US7632636B2 (en) * 2004-09-21 2009-12-15 Boehringer Ingelheim Vetmedica, Inc. Porcine reproductive and respiratory syndrome isolates and methods of use
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US7833707B2 (en) * 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
US20060251827A1 (en) * 2005-05-09 2006-11-09 Applied Materials, Inc. Tandem uv chamber for curing dielectric materials
PT2369001T (pt) 2005-06-24 2016-10-25 Univ Minnesota Vírus srrp, clones infecciosos, os seus mutantes e processos de utilização
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
PL2368572T3 (pl) 2005-11-04 2020-11-16 Seqirus UK Limited Szczepionki z adjuwantem z niewirionowymi antygenami otrzymane z wirusów grypy hodowanych w hodowli komórkowej
US20090220541A1 (en) * 2005-11-04 2009-09-03 Novartis Vaccines And Diagnostics Srl Emulsions with free aqueous-phase surfactant for adjuvanting split influenza vaccines
EP2275132B1 (en) 2005-12-29 2021-03-03 Boehringer Ingelheim Animal Health USA Inc. Multivalent PCV2 immunogenic compositions and methods of producing them
MX338626B (es) 2005-12-29 2016-04-26 Boehringer Ingelheim Vetmed Uso de una composicion inmunogenica de pcv2 para producir los sintomas clinicos en cerdos.
ATE535253T1 (de) * 2006-04-10 2011-12-15 Intervet Int Bv Impfstoff gegen mycoplasma prrsv
EP2859900A1 (en) * 2006-12-11 2015-04-15 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
BRPI0721083A2 (pt) * 2006-12-15 2014-02-25 Boehringer Ingelheim Vetmed Tratamento de porcos com antígeno de pcv2
EP1941903A1 (en) * 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
CL2008001806A1 (es) * 2007-06-20 2008-09-05 Wyeth Corp Composicion de vacuna en emulsion agua en aceite que comprende un antigeno y un adyuvante en la fase acuosa; y metodo de elaboracion.
US20090017064A1 (en) * 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
CN104043116A (zh) * 2007-11-06 2014-09-17 硕腾W有限责任公司 猪肺炎支原体无毒力佐剂化活疫苗
AU2012261741B2 (en) * 2007-11-06 2016-02-25 Zoetis Services Llc Mycoplasma hyopneumoniae avirulent-adjuvanted live vaccine
JP2011508595A (ja) * 2007-12-31 2011-03-17 ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド 外来性アミノ酸の挿入を含むｐｃｖ２ｏｒｆ２ウイルス様粒子
JP5613061B2 (ja) * 2008-01-23 2014-10-22 ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド Ｐｃｖ２マイコプラズマ・ハイオニューモニエ免疫原性組成物および前記組成物の製造方法
US20110033495A1 (en) * 2008-02-15 2011-02-10 Boehringer Ingelheim Vetmedica, Inc. Methods and compositions for reducing the impact of enteric diseases
US8444989B1 (en) 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
CN101363865B (zh) * 2008-05-26 2013-03-06 北京庄笛浩禾生物医学科技有限公司 一种猪蓝耳病毒胶体金检测试纸条、其制备方法及其应用
NZ590010A (en) * 2008-06-25 2013-01-25 Braasch Biotech Llc Compositions and methods treating growth hormone deficiency and/or an insulin-like growth factor 1 deficiency with somatostatin and an adjuvant
US20100003278A1 (en) * 2008-07-03 2010-01-07 Boehringer Ingelheim Vetmedica, Inc. Immunological Compositions Effective for Lessening the Severity or Incidence of PRRSV Signs and Methods of Use Thereof
KR101653177B1 (ko) * 2008-08-25 2016-09-01 베링거잉겔하임베트메디카인코퍼레이티드 고병원성 돼지 생식기 및 호흡기 증후군(ｈｐ ｐｒｒｓ)에 대한 백신
AU2010212550B2 (en) 2009-02-10 2016-03-10 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP2609428B1 (en) * 2010-08-27 2016-02-10 Intervet International B.V. Potency test for vaccine formulations
US8546149B2 (en) 2010-08-27 2013-10-01 Intervet Inc. Potency test for vaccine formulations
CN101954079B (zh) * 2010-09-21 2012-11-28 江苏省农业科学院 猪支原体肺炎活疫苗的疫苗佐剂及其制备方法和应用
CA2827337C (en) 2011-02-17 2019-07-09 Boehringer Ingelheim Vetmedica Gmbh Commercial scale process for production of prrsv
ES2692809T3 (es) 2011-02-17 2018-12-05 Boehringer Ingelheim Vetmedica Gmbh Nueva cepa del PRRSV europea
SMT201800284T1 (it) 2011-06-10 2018-07-17 Univ Oregon Health & Science Glicoproteine cmv e vettori ricombinanti
US9187731B2 (en) 2011-07-29 2015-11-17 Boehringer Ingelheim Vetmedica Gmbh PRRS virus inducing type I interferon in susceptible cells
US9315781B2 (en) 2011-07-29 2016-04-19 Boehringer Ingelheim Vetmedica Gmbh Infectious CDNA clone of european PRRS virus and uses thereof
CN103157100B (zh) * 2011-12-08 2014-09-24 普莱柯生物工程股份有限公司 副猪嗜血杆菌病、猪链球菌病二联灭活疫苗及其制备方法
US9474692B2 (en) 2012-01-13 2016-10-25 Boehringer Ingelheim Vetmedica Gmbh Kit for the preparation of a vaccinating agent
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
UA121097C2 (uk) 2012-12-28 2020-04-10 Бьорінгер Інгельхайм Ветмедіка Гмбх Імуногенна композиція, що містить антигени мікоплазм
DK2938747T3 (da) 2012-12-28 2019-08-05 Boehringer Ingelheim Vetmedica Gmbh Fremgangsmåde til fremstilling af en mycoplasma vaccine
CN103908665B (zh) * 2013-01-05 2016-05-25 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
CN103071151B (zh) * 2013-01-17 2014-07-23 江苏省农业科学院 猪支原体肺炎疫苗专用稀释剂及其制备方法
CN103961695B (zh) * 2013-02-06 2016-09-07 普莱柯生物工程股份有限公司 一种预防和治疗猪呼吸道综合征的疫苗组合物及其制备方法和应用
US9579373B2 (en) 2013-03-15 2017-02-28 Boehringer Ingelheim Vetmedica, Inc. Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
CN104096222B (zh) * 2013-04-08 2016-09-14 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
ES2882374T3 (es) 2013-05-08 2021-12-01 Pharmgate Biologics Inc Vacuna para PCV2 y micoplasma
KR102319843B1 (ko) 2013-09-25 2021-10-29 조에티스 서비시즈 엘엘씨 Pcv2b 분지형 백신 조성물 및 사용 방법
US9505808B2 (en) 2013-10-02 2016-11-29 Boehringer Ingelheim Vetmedica, Inc. PCV2 ORF2 protein variant and virus like particles composed thereof
CN104248759B (zh) * 2013-11-19 2017-05-10 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
CN104857508B (zh) * 2014-02-21 2018-03-16 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
US10064930B2 (en) * 2015-01-16 2018-09-04 Boehringer-Ingelheim Vermedica, Inc. Immunogenic compositions and methods for pigeon fever
KR102829941B1 (ko) * 2015-11-13 2025-07-04 타르간 인크. 동물에 물질을 주입하기 위한 자동 시스템 및 방법
CN111346224B (zh) 2018-12-24 2023-12-08 洛阳赛威生物科技有限公司 一种免疫佐剂组合物及其制备方法和应用
CN112618710B (zh) * 2019-09-24 2023-09-29 华南理工大学 一种植物糖原猪口服接种疫苗纳米佐剂及其制备方法与应用
TW202510910A (zh) * 2023-06-28 2025-03-16 國立感染症研究所長代表之日本國 疫苗佐劑組成物及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3790665A (en) * 1968-02-23 1974-02-05 Haver Lockhart Labor Inc Injectable adjuvant,method of preparing same and compositions including such adjuvant
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
CA1267087A (en) * 1985-02-14 1990-03-27 Nicolaas Visser Synthetic immunogen
ZA881694B (en) 1987-03-17 1988-09-06 Akzo N.V. Adjuvant mixture
AU626271B2 (en) 1987-11-03 1992-07-30 Syntex (U.S.A.) Inc. Vaccine adjuvant
ZA906806B (en) * 1989-08-31 1991-06-26 Ici Australia Operations Plants
ATE160699T1 (de) * 1990-05-29 1997-12-15 American Cyanamid Co Impfstoff gegen die pneumonie bei schweinen und verfahren zu seiner herstellung
US5565205A (en) * 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
US5338543A (en) * 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
WO1995030437A1 (en) 1994-05-10 1995-11-16 American Home Products Corporation Improved modified live brsv vaccine
UA78180C2 (uk) * 1997-10-03 2007-03-15 Меріаль Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
US6517843B1 (en) * 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
US6632439B2 (en) * 1999-09-29 2003-10-14 Novartis Animal Health, Inc. Fusobacterium necrophorum vaccine and method for making such vaccine
US6585981B1 (en) * 2000-07-27 2003-07-01 Regents Of The University Of Minnesota Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae
MY129765A (en) * 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine

Also Published As

Publication number Publication date
JP2006515304A (ja) 2006-05-25
BR0310082A (pt) 2007-04-10
DK1870109T3 (en) 2016-04-25
MXPA04011218A (es) 2005-02-14
US20070134269A1 (en) 2007-06-14
JP2013189438A (ja) 2013-09-26
HRP20041068A2 (en) 2004-12-31
RS54390B1 (sr) 2016-04-28
US7018638B2 (en) 2006-03-28
TW200306854A (en) 2003-12-01
WO2004058142A2 (en) 2004-07-15
CL2010000397A1 (es) 2010-10-15
AR039545A1 (es) 2005-02-23
US7622124B2 (en) 2009-11-24
JP5700861B2 (ja) 2015-04-15
KR20050007402A (ko) 2005-01-17
ES2569063T3 (es) 2016-05-06
ES2431988T3 (es) 2013-11-29
KR101056622B1 (ko) 2011-08-16
HK1111103A1 (en) 2008-08-01
US20060228373A1 (en) 2006-10-12
AU2003303129B2 (en) 2009-10-08
EP1506006A2 (en) 2005-02-16
EP1870109A1 (en) 2007-12-26
CN1652817A (zh) 2005-08-10
NZ537014A (en) 2009-09-25
TWI320715B (en) 2010-02-21
ZA200410153B (en) 2014-07-30
HRP20041068B1 (hr) 2018-10-05
US7169394B2 (en) 2007-01-30
US7959927B2 (en) 2011-06-14
RS99704A (sr) 2006-12-15
US20030017171A1 (en) 2003-01-23
US20100062018A1 (en) 2010-03-11
EP1870109B1 (en) 2016-03-16
AU2003303129A1 (en) 2004-07-22
EP1506006B1 (en) 2013-07-31
WO2004058142A3 (en) 2004-11-04
CN1305524C (zh) 2007-03-21
ME00569A (en) 2011-12-20

Similar Documents

Publication Publication Date Title
AR039545A1 (es) Vacuna de bacterina de mycoplasma hyopneumoniae mejorada
CN1315534C (zh) 用于牛呼吸系统和生殖系统的疫苗
EP2217271B1 (en) Mycoplasma hyopneumoniae avirulent -adjuvanted live vaccine
CN101175509B (zh) 含有胞内劳森菌的免疫原性组合物
US9364527B2 (en) Bovine vaccines and methods
ME00570A (en) Improved mycoplasma hyopneumoniae bacterin vaccine
Marchioro et al. Local and systemic immune responses in pigs intramuscularly injected with an inactivated Mycoplasma hyopneumoniae vaccine
US11103569B2 (en) Vaccine for protection against Streptococcus suis
CA2646574C (en) Vaccine against mycoplasma and prrsv
US20050089533A1 (en) Canine vaccines against Bordetella bronchiseptica
US20210369832A1 (en) Vaccine for protection against streptococcus suis
US5695769A (en) Pasteurella multocida toxoid vaccines
WO2011015614A1 (en) A vaccine directed against porcine pleuropneumonia and a method to obtain such a vaccine
Brogden et al. Protection of ruminants by Pasteurella haemolytica A1 capsular polysaccharide vaccines containing muramyl dipeptide analogs
US20240197851A1 (en) A vaccine for protection against streptococcus suis serotype 9, sequence type 16
JP4105220B2 (ja) 精巣ｂｖｄｖ感染に対するワクチン接種方法
WO2022072431A1 (en) Novel pasteurella multocida strains and vaccines having hyac and nanp deletions
US20220098558A1 (en) Novel pasteurella multocida strains and vaccines having hyac and nanp deletions
WO2025064844A9 (en) Porcine sapovirus isolates and immunogenic compositions therefrom
WO2004043286A3 (en) Use of rmlt as a marker antigen for vaccines and as a synergistic adjuvant with amphigen
Eichmeyer et al. Efficacy of Ingelvac® PRRS MLV when rehydrated with a combination of Ingelvac MycoFLEX® and Ingelvac CircoFLEX®
EP0614371A1 (en) Pasteurella multocida toxoid vaccines
TH60396A (th) Mycoplasma Hyopneumoniae แบคเทอรินวัคซีนที่ได้?รับการปรับปรุงให้ดีขึ้น
Fangman et al. Serologic response of weaned pigs vaccinated with 3FLEX™ is similar to pigs vaccinated with Ingelvac® CircoFLEX-MycoFLEX™ and Ingelvac® PRRS MLV in separate injections
HK1112839B (en) Multivalent canine vaccines against leptospira bratislava and other pathogens